These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24802891)

  • 1. A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign?
    Ohlin M
    Mol Immunol; 2014 Aug; 60(2):95-102. PubMed ID: 24802891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-germ-line encoded residues are critical for effective antibody recognition of a poorly immunogenic neutralization epitope on glycoprotein B of human cytomegalovirus.
    Lantto J; Lindroth Y; Ohlin M
    Eur J Immunol; 2002 Jun; 32(6):1659-69. PubMed ID: 12115649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors.
    Ishibashi K; Tokumoto T; Shirakawa H; Hashimoto K; Ikuta K; Kushida N; Yanagida T; Shishido K; Aikawa K; Toma H; Inoue N; Yamaguchi O; Tanabe K; Suzutani T
    Transpl Infect Dis; 2011 Jun; 13(3):318-23. PubMed ID: 20804536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
    Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties.
    Barrios Y; Knör S; Lantto J; Mach M; Ohlin M
    Mol Immunol; 2007 Feb; 44(5):680-90. PubMed ID: 16824601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies.
    Schrader JW; McLean GR
    Immunol Lett; 2007 Sep; 112(1):58-60. PubMed ID: 17714794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus.
    Wiegers AK; Sticht H; Winkler TH; Britt WJ; Mach M
    J Virol; 2015 Jan; 89(1):361-72. PubMed ID: 25320309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding characteristics determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein B of human cytomegalovirus.
    Lantto J; Fletcher JM; Ohlin M
    Virology; 2003 Jan; 305(1):201-9. PubMed ID: 12504553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
    Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
    Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Strain-Specific Neutralizing Epitope on Glycoprotein H of Human Cytomegalovirus.
    Thomas M; Kropff B; Schneider A; Winkler TH; Görzer I; Sticht H; Britt WJ; Mach M; Reuter N
    J Virol; 2021 Aug; 95(18):e0065721. PubMed ID: 34160252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immune response to functional regions of human cytomegalovirus glycoprotein B.
    Navarro D; Lennette E; Tugizov S; Pereira L
    J Med Virol; 1997 Aug; 52(4):451-9. PubMed ID: 9260696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
    Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step.
    Ye X; Su H; Wrapp D; Freed DC; Li F; Yuan Z; Tang A; Li L; Ku Z; Xiong W; Jaijyan D; Zhu H; Wang D; McLellan JS; Zhang N; Fu TM; An Z
    PLoS Pathog; 2020 Aug; 16(8):e1008736. PubMed ID: 32745149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of epitopes of human monoclonal antibodies against cytomegalovirus glycoprotein B for neutralization and antibody-dependent phagocytosis.
    Yamaguchi K; Shimizu H; Takahashi K; Nagatomo T; Nishimura T; Matsumoto M; Koshizuka T; Mori H; Inoue N; Torikai M
    Vaccine; 2023 Jul; 41(31):4497-4507. PubMed ID: 37321896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.
    Baraniak I; Kropff B; McLean GR; Pichon S; Piras-Douce F; Milne RSB; Smith C; Mach M; Griffiths PD; Reeves MB
    J Infect Dis; 2018 May; 217(12):1907-1917. PubMed ID: 29528415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
    Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies to gB based CMV vaccine requires full length antigen but reduced virus neutralization on non-fibroblast cells limits vaccine efficacy in the guinea pig model.
    Choi KY; El-Hamdi NS; McGregor A
    Vaccine; 2020 Feb; 38(10):2340-2349. PubMed ID: 32008881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines.
    Axelsson F; Adler SP; Lamarre A; Ohlin M
    Vaccine; 2007 Dec; 26(1):41-6. PubMed ID: 18063447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies.
    Ohlin M; Sundqvist VA; Mach M; Wahren B; Borrebaeck CA
    J Virol; 1993 Feb; 67(2):703-10. PubMed ID: 7678304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Fully Protective Congenital CMV Vaccine Requires Neutralizing Antibodies to Viral Pentamer and gB Glycoprotein Complexes but a pp65 T-Cell Response Is Not Necessary.
    Choi KY; McGregor A
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.